trial

Galantamine for Cognitive Deficits in Schizophrenia

NCTId NCT00463879
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Completed
Enrollment 21 (actual)
Sponsored by Yale University
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Completed
Enrollment
21 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2005-09
Primary completion
—
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Galantamine

Sponsors

Yale UniversityLead Sponsor
National Alliance for Research on Schizophrenia and DepressionCollaborator

Investigators

1
Tony P George, M.D.Principal Investigator

Sites

1 total
New Haven, United States

Facts & assertions

3 sourced
Enrollment
21
Phase
PHASE2,PHASE3
Status
COMPLETED
relationships
The graph out of here
drug
Galantamine
drug
lead_sponsor
Yale University
company
collaborator
National Alliance for Research on Schizophrenia and Depression
company
indication
Smoking
indication
Schizophrenia
indication
Cognition Disorders
indication
investigator
Tony P George, M.D.
person